Assess the efficacy of abobotulinum toxin A (Dysport®) injection in salivary glands for drooling treatment
Descriptive and cross sectional study. abobotulinum toxin A injection in bilateral parotid and submandibular glands, dose range from 100 to 125 units per gland with ultrasound guidance. Results were measured at 4 to 6 weeks after treatment by specific objectives in the Goal Attainment Scaling (GAS).
14 patients were included in the study. Mean age 14.9 years; 10 patients with cerebral palsy, 3 with severe intellectual disability, 1 patient with Amyotrophic Lateral Sclerosis (ALS). 11 from 14 individuals (78.57%) fulfilled specific goals measured by GAS after BoNT- A injection (Decrease of 50% in the number of bibs used during the day, decrease of 50% of drooling perception by the caregiver). 3 patients (21%) presented some dysphagia in the first two weeks after BoNT injection without penetration or aspiration evidenced by clinical and paraclinical tests.
Abobotulinum toxin A injection showed efficacy in drooling treatment in 78.57% of the patients. Mild dysphagia was observed in 21% of individuals without experiencing life threatening conditions.